GlassScriptPhysician profile
Laura Sergis
NPI 1598866527
$3,717.86
in general payments reported to CMS, 2019-2025
25 companies · $693 in 2025
The $693 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $301 · 2021: $514 · 2022: $435 · 2023: $647 · 2024: $506 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $613.45 | 2019-2025 | Vaxneuvance, Vaxelis, Rotateq |
| Glaxosmithkline, LLC. | $506.83 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Corium, LLC | $490.23 | 2021-2025 | Azstarys |
| Pfizer INC. | $393.40 | 2019-2023 | |
| Sanofi Pasteur INC. | $345.73 | 2019-2025 | |
| Kaleo, INC. | $190.23 | 2019-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $176.12 | 2023-2025 | |
| Sobi, INC | $149.28 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.90 | 2020-2022 | |
| Cranial Technologies, INC | $130.42 | 2019-2025 | Doc Band |
| Genentech USA, INC. | $89.77 | 2019-2021 | |
| Phadia US INC. | $83.25 | 2021-2024 | Immunocap |
| Organon LLC | $60.99 | 2025 | Vtama |
| Ars Pharmaceuticals Operations, INC. | $47.70 | 2025 | Neffy |
| Adlon Therapeutics L.P. | $45.35 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $41.21 | 2021-2023 | Flumist Quadrivalent |
| Seqirus USA INC | $39.51 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Genzyme Corporation | $29.36 | 2024 | |
| Alk-Abello, INC | $28.92 | 2025 | Neffy |
| Verrica Pharmaceuticals INC. | $24.59 | 2025 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $22.59 | 2024 | Dupixent |
| Lnhc, INC | $21.35 | 2025 | Zelsuvmi |
| Kowa Pharmaceuticals America, INC. | $13.95 | 2025 | Zoryve |
| Smith+Nephew, INC. | $13.61 | 2019 | |
| Bardy Diagnostics, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Sergis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.